Activity release date: May 31, 2009
Expiration date: May 31, 2010
The program will be oriented to a target audience of Medical oncologists, radiation oncologists, gastroenterologists, surgeons, surgical oncologists, diagnostic radiologists, internists, family practitioners and other allied health care professionals who treat patients with gastrointestinal neoplasms.
Gastrointestinal malignancies are a major source of cancer deaths throughout the world. Colorectal cancer will be diagnosed in 153,760 Americans and an estimated 52,180 will die of the disease by the end of 2007. New cases of liver, stomach and pancreatic cancers will be diagnosed in an additional 77,590 Americans with 61,360 of these patients dying of their disease by the end 2007. Heterogeneous in nature the management of all these cancers presents complex clinical problems, requiring an ever-evolving multidisciplinary approach to diagnosis and treatment. Recognizing that patient quality of life and survival are significantly improved when these cancers are detected early and treated appropriately, there is a need for physicians to remain current on advances in the diagnosis and treatment of these gastrointestinal malignancies.
Despite advances in the treatment of gastrointestinal (GI) cancers, prognosis remains poor. In recent years, the introduction of new therapeutic agents, particularly targeted agents, has brought new hope that GI malignancies might soon become more effectively managed. Improved combination drug regimens and treatment strategies are being developed as new mechanisms of action of targeted agents are discovered. The interaction between targeted agents and cytotoxic agents, the optimal integration of targeted therapy, chemotherapy, radiotherapy, and surgical resection all are important factors for improving patient outcomes.
The content presented in the Advances in the Multidisciplinary Treatment of Gastrointestinal Neoplasms webcast was designed by experts in the field of gastrointestinal oncology. Controversies in key areas will be examined, and changes in treatment paradigms will be profiled and discussed in a multimedia format of synchronized slide and audio files.
At the conclusion of this educational activity participants should be able to:
The City of Hope National Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The City of Hope National Medical Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.
The City of Hope National Medical Center adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
The following City of Hope National Medical Center CME Committee members/planners have indicted they have nothing to disclose: Lucille Leong, MD, Crystal Saavedra, Anna Pawlowska, MD, Karl Gaal, MD, Mary Mendelsohn, Jo Hanson, Christina Eckhart, Khanh Nguyen, MD, Paul Lin, MD, and Teresa Ball.
The following planners have indicated a conflict with the following corporate organizations:
Any potential conflicts relative to the previous disclosure have been resolved.
The employees of CJP Medical Communications have no financial relationships to disclose.
Robert Morgan, Jr, MD, FACP
Director, Continuing Medical Education
Associate Director for Education
Department of Medical Oncology &Therapeutics Research
City of Hope
Duarte, California
Stephen Shibata, MD
Director, GI Oncology Program
Department of Medical Oncology & Therapeutics Research
City of Hope
Duarte, California
Lily Lai, MD
Staff Surgeon
Department of General & Oncologic Surgery
City of Hope
Duarte, California
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
This activity has been developed through independent educational grants received from Eli Lilly, Merck, and OSI Pharmaceuticals, Inc.
There are no fees for participating in this CME activity. To receive credit during the period May 31, 2009 to May 31, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
The posttest can be accessed at the end of the activity. Please e-mail any questions to jkagan@coh.org.
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Carden Jennings Publishing and the City of Hope present this resource for educational purposes only. Participants are expected to use their own expertise and judgment while engaged in the practice of medicine. Please consult full prescribing information for any drugs or procedures discussed within this activity. The views and opinions expressed in these presentations are those of the authors and do not necessarily reflect the views of the co-sponsors, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, City of Hope and Carden Jennings Publishing and their servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
This reference may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.
All rights reserved; for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.
PC UsersIf you need to upgrade your Web browser, follow one of the links listed below:
Compatible Web browsers include:
Carden Jennings Publishing may collect standard Web traffic data such as the time and date of visit. Carden Jennings Publishing uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Carden Jennings Publishing does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Carden Jennings Publishing does, when required, provide the minimum subset of information to third parties that are responsible for accreditation and issuance of certification of CME/CE tests submitted. By participating in the Web-based activity, you agree that Carden Jennings Publishing has full permission to provide this minimum subset of information to third parties as required by law.
For CME questions, please contact jkagan@coh.org or call 626-256-HOPE (4673), Ext. 65626. If you experience technical difficulties, please contact jgolden@cjp.com.